Skip to Content

Congratulations to our Clients!

November 5, 2020

We are pleased to share exciting news from our clients and celebrate their recent successes! was acquired by Press Ganey. Shulman Rogers was pleased to represent in this complex and fast-moving M&A transaction that was completed in just 45 days!

Neuraly Inc. received FDA clearance for an investigational new drug application for patients with Alzheimer’s and Parkinson’s disease.

Adaptive Phage Therapeutics is deploying its investigational PhageBank™ therapy in response to a deadly outbreak of secondary infections in COVID-19 patients with expectations of reducing mortality rates by over 30%. APT also received FDA orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™.